Radiopharm Theranostics Announces Promising Preclinical Findings
Radiopharm Theranostics, a dynamic clinical-stage biopharmaceutical firm, has unveiled exciting preclinical results pertaining to its Lu177-B7H3 monoclonal antibody (mAb) program, RV01. This progression indicates a favorable trajectory towards the company's aim of initiating groundbreaking therapeutic studies in solid tumours, particularly as they plan to advance RV01 into first-in-human trials.
Key Findings from Preclinical Studies
The early data shows notably positive biodistribution characteristics along with commendable tumour uptake rates of the RV01 treatment, which is crucial for the drug's effectiveness. This research indicates that RV01 not only targets cancerous cells efficiently but also minimizes exposure and potential toxicities typical of conventional therapies. Unlike many traditional monoclonal antibodies, RV01 has an expedited half-life due to specific Fc region modifications, allowing faster clearance from the body.
Advancements in Antibody Technology
The innovation behind RV01 stems from its specialization in targeting the B7-H3 protein, a marker that is prevalent in numerous solid tumours. The design leverages its strong binding affinity specifically to the 4Ig isoform of B7-H3, which is linked to poorer prognoses in various cancer types. This targeted approach aims to enhance efficacy while reducing adverse side effects associated with broader-spectrum treatments.
Statements from Company Officials
Chief Medical Officer, Dr. Dimitris Voliotis, expressed optimism regarding the new findings. He mentioned, "The latest preclinical data validate our previous results, confirming our mAb's effective targeting capabilities, coupled with a significantly reduced half-life. Our modifications aim to streamline the therapeutic window of RV01 to combat tumours effectively while minimizing unnecessary exposures."
His sentiments were echoed by CEO Riccardo Canevari, who remarked on the importance of this biodistribution data. It finalizes the preclinical package required for filing an Investigational New Drug (IND) application, marking a pivotal step towards the upcoming Phase 1 trial.
Implications for Future Trials
The anticipated IND application filing by mid-2025 suggests a vigorous commitment to pioneering cancer treatment modalities. The Phase 1 trial is set to evaluate the safety and efficacy of RV01 and is projected to commence by the end of the year. Such trials represent a critical intersection of research and therapeutic practice that could reshape treatment landscapes for solid tumour cancers.
About Radiopharm Theranostics
Radiopharm Theranostics is consistently committed to revolutionizing the realm of cancer therapeutics with its advanced technologies in radiopharmaceuticals. With a diverse range of products and a comprehensive clinical pipeline that encompasses multiple phases of trials across different cancer types, the company is strategically positioned to address significant unmet medical needs efficiently.
Radiopharm is traded on the Australian Stock Exchange under the ticker RAD and on NASDAQ as RADX. Their focus on innovative therapies aims at not only treating cancers but also improving the quality of life for patients through specialized treatments tailored to individual needs.
Contact Information
For inquiries regarding investor relations:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ
E: annemarie.fields@precisionaq.com
For media-related queries:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Frequently Asked Questions
What is Lu177-B7H3-mAb?
Lu177-B7H3-mAb is a targeted radiopharmaceutical therapy developed by Radiopharm Theranostics, focusing on specific cancer markers to enhance treatment efficacy.
What are the goals of the RV01 program?
The RV01 program aims to successfully transition to first-in-human studies to assess safety and efficacy in patients with solid tumours.
Why is the Fc region modification important?
Fc region modifications in RV01 result in a shorter half-life, which helps to reduce off-target exposure and associated toxicities in patients.
When will the Phase 1 trial start?
The Phase 1 trial is expected to commence by the end of the year following the filing of the IND application in mid-2025.
How does Radiopharm Theranostics contribute to oncology?
Radiopharm Theranostics develops innovative radiopharmaceuticals designed to treat various forms of cancer effectively, emphasizing personalized treatment approaches.
